MET and hepatocellular carcinoma: Also, miR-26a inhibits tumor growth, metastasis and angiogenesis of HCC via targeting HGF-induced c-Met signaling pathways and FBXO11, ST3GAL5 signaling pathways (Yang et al., 2014; Cai et al., 2017; Ma et al., 2018).